Skip to main content
SpringerLink
Log in

Sitagliptin: A Review in Type 2 Diabetes

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia®; Glactiv®; Tesavel®; Xelevia™) is approved in more than 130 countries worldwide as monotherapy and in combination with other antihyperglycaemic drugs for the treatment of adult patients with type 2 diabetes (T2D). Extensive clinical experience has firmly established the glycaemic efficacy of oral sitagliptin (±other antihyperglycaemic drugs) in a broad spectrum of patients with T2D, including obese, elderly and renally impaired patients and those with established cardiovascular (CV) disease (CVD). Sitagliptin is generally well tolerated, with most adverse events being of mild to moderate intensity and relatively few patients discontinuing treatment because of these events. Sitagliptin treatment was not associated with an increased risk for the known CVD risk factors of hypoglycaemia and bodyweight gain. Of note, in the TECOS CV safety trial in patients with T2D and established CVD, sitagliptin was noninferior to placebo in terms of the risk of the 4-point major adverse cardiac event (MACE) outcome, with no increased risk in hospitalization for heart failure. Albeit discussion is equivocal regarding the potential increased risk of pancreatitis and pancreatic cancer with incretin-based therapies (including sitagliptin), no causal link between incretin-based drugs and these events has been established to date. With its convenient once-daily oral regimen, low potential for pharmacokinetic drug–drug interactions and good efficacy and safety profiles, including CV safety, sitagliptin remains an important option in the management of patients with T2D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489–512.

    Article  CAS  PubMed  Google Scholar 

  2. Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(2):223–42.

    Article  CAS  PubMed  Google Scholar 

  3. Lyseng-Williamson KA. Sitagliptin. Drugs. 2007;67(4):587–97.

    Article  CAS  PubMed  Google Scholar 

  4. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):442–51.

    Article  CAS  PubMed  Google Scholar 

  5. Mita T, Katakami N, Shiraiwa T, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). Diabetes Care. 2016;39(9):455–64.

    Article  CAS  PubMed  Google Scholar 

  6. Ishikawa S, Shimano M, Watarai M, et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol. 2014;114(3):384–8.

    Article  CAS  PubMed  Google Scholar 

  7. Oyama J-I, Murohara T, Kitakaze M, et al. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. PLoS Med. 2016;13(6):e1002051.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bloomfield DM, Krishna R, Hreniuk D, et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol. 2009;49(8):937–46.

    Article  CAS  PubMed  Google Scholar 

  9. Merck Sharp & Dohme Corp. Januvia® (sitagliptin) tablets: US prescribing information. 2016. https://www.merck.com/. Accessed 26 Sep 2016.

  10. European Medicines Agency. Januvia 25 mg film-coated tablets: summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 26 Sep 2016.

  11. Bergman A, Mistry GC, Luo WL, et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28(6):307–13.

    Article  CAS  PubMed  Google Scholar 

  12. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28(6):315–22.

    Article  CAS  PubMed  Google Scholar 

  13. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos. 2007;35(4):533–8.

    Article  CAS  PubMed  Google Scholar 

  14. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30(7):1862–4.

    Article  CAS  PubMed  Google Scholar 

  15. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56.

    Article  CAS  PubMed  Google Scholar 

  16. Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–9.

    Article  CAS  PubMed  Google Scholar 

  17. Mathieu C, Shankar RR, Lorber D, et al. A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine. Diabetes Ther. 2015;6(2):127–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):252–61.

    Article  CAS  PubMed  Google Scholar 

  19. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of -cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65(2):154–64.

    Article  CAS  PubMed  Google Scholar 

  21. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–43.

    Article  CAS  PubMed  Google Scholar 

  22. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.

    Article  CAS  PubMed  Google Scholar 

  23. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.

    Article  CAS  PubMed  Google Scholar 

  24. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–9.

    Article  CAS  PubMed  Google Scholar 

  25. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycaemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36:2508–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lavalle-Gonázlez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.

    Article  Google Scholar 

  27. Ahren B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141–8.

    Article  CAS  PubMed  Google Scholar 

  28. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167–77.

    Article  PubMed  Google Scholar 

  32. Van Gaal L, Souhami E, Zhou T, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus. J Clin Transl Endocrinol. 2014;1(2):31–7.

    Article  Google Scholar 

  33. Hartley P, Shentu Y, Betz-Schiff P, et al. Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, non-inferiority trial. Drugs Aging. 2015;32:469–76.

    Article  CAS  PubMed  Google Scholar 

  34. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–58.

    Article  CAS  PubMed  Google Scholar 

  35. Shankar RR, Xu L, Golm GT, et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. Int J Clin Pract. 2015;69(6):626–31.

    Article  CAS  PubMed  Google Scholar 

  36. Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocrine Disorders. 2015;15:34.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36(5):1067–73.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Kothny W, Lukashevich V, Foley JE, et al. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia. 2015;58(9):2020–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013;61(4):579–87.

    Article  PubMed  Google Scholar 

  40. Montilla S, Marchesini G, Sammarco A, et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metabol Cardiovasc Dis. 2014;24(12):1346–53.

    Article  CAS  Google Scholar 

  41. Nyeland ME, Ploug UJ, Richards A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69(3):281–91.

    Article  CAS  PubMed  Google Scholar 

  42. Ohmura H, Mita T, Taneda Y, et al. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes. J Clin Med Res. 2015;7(4):211–9.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Chen T-Y, Hsieh C-J. Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus. Postgrad Med. 2014;126(3):205–15.

    Article  PubMed  Google Scholar 

  44. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.

    Article  CAS  PubMed  Google Scholar 

  45. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular risks. Am Heart J. 2013;166(6):983–9.e7.

  46. Bethel MA, Engel SS, Ding J, et al. Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience [abstract]. Diabetologia. 2016;59(Suppl 1):S369.

    Google Scholar 

  47. Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: oucomes from TECOS. Diabetes Care. 2016;. doi:10.2337/dc16-1415.

    PubMed  Google Scholar 

  48. Engel SS, Round E, Golm GT, et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther. 2013;4(1):119–45.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31(3):203–14.

    Article  CAS  PubMed  Google Scholar 

  50. Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl. 3):57–64.

    Article  CAS  PubMed  Google Scholar 

  52. Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016;7(17):24871–9.

    PubMed  PubMed Central  Google Scholar 

  53. Josse RG, Majumdar SR, Zheng Y, et al. Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. Diabetes Obes Metab. 2016. doi:10.1111/dom.12786.

  54. Engel SS, Suryawanshi S, Josse RG, et al. Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascualr Outcomes with Sitagliptin (TECOS) [abstract no. 759]. Diabetologia. 2016;59(Suppl 1):S361.

    Google Scholar 

  55. Bethel MA, Green JB, Milton J, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015;17(4):395–402.

    Article  CAS  PubMed  Google Scholar 

  56. McGuire DK, Van de Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(2):126–35.

    Article  PubMed  Google Scholar 

  57. Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12(1):3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Zhang B, Zhong YI, Lu Z. Sitagliptin and risk of hypertension in patients with type 2 diabetes mellitus: meta-analysis of randomized trials [abstract no. P5038]. Eur Heart J. 2015;36(Suppl 1):877–8.

    Google Scholar 

  59. Shin S, Kim H. The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. Ther Clin Risk Manag. 2016;12:435–44.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Tseng C-H. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Oncotarget. 2016;7(38):62687–96.

    PubMed  Google Scholar 

  61. Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–82.

    Article  PubMed  Google Scholar 

  62. Sheehan JJ, Tsai K, Johnston S, et al. Risk of hospitalisation for heart failure between dipeptidyl peptidase 4 inhibitors vs sulfonylureas and saxagliptin vs sitagliptin in a US claims database [abstract no. 370]. Diabetologia. 2015;58(Suppl 1):S186.

    Google Scholar 

  63. Buse JB, Bethel MA, Green JB, et al. Pancreatic safety of sitagliptin in the TECOS study. Diabetes Care. 2016;. doi:10.2337/dc15-2780.

    Google Scholar 

  64. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    Article  CAS  PubMed  Google Scholar 

  65. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

    Article  CAS  PubMed  Google Scholar 

  66. Tseng C-H. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: a retrospective cohort analysis of the National Health Insurance database in Taiwan. Ann Med. 2015;47(7):561–9.

    Article  CAS  PubMed  Google Scholar 

  67. Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2016;46(1):70–9.

    Article  CAS  PubMed  Google Scholar 

  68. Chang CH, Lin JW, Chen ST, et al. Dipeptidyl peptidase-4 inhibitor use is not associated with acute pancreatitis in high-risk type 2 diabetic patients: a nationwide cohort study. Medicine. 2016;95(7):e2603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Int Med. 2013;173(7):534–9.

    Article  CAS  Google Scholar 

  70. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. International Diabetes Federation. Diabetes and cardiovascular disease. 2016. www.idf.org/cvd. Accessed 27 Oct 2016.

  72. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med. 2016;164:542–52.

    Article  PubMed  Google Scholar 

  73. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.

    Article  PubMed  Google Scholar 

  74. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2016;39(Suppl 1):S60–71.

    Google Scholar 

  75. American Diabetes Association. Glycaemic targets. Diabetes Care. 2016;39(Suppl 1):S39–46.

    Google Scholar 

  76. American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care. 2016;39(Suppl 1):S47–51.

    Google Scholar 

  77. American Diabetes Association. Approaches to glycaemic treatment. Diabetes Care. 2016;39(Suppl 1):S52–9.

    Google Scholar 

  78. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.

    Article  CAS  PubMed  Google Scholar 

  79. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2016 executive summary. Endocr Pract. 2016;22:84–113.

    Article  PubMed  Google Scholar 

  80. National Institute for Health Care and Excellence. Type 2 diabetes in adults: management (NG28). 2016. www.nice.org.uk/guidance/ng28. Accessed 27 Oct 2016.

  81. Garber AJ, Abrahamson MJ, Blonde L, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21(4):438–47.

    Article  PubMed  Google Scholar 

  82. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:2013–216.

    Article  Google Scholar 

  83. Zhao JY, Wang HP, Wang HJ, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus: a meta-analysis. Int J Clin Exp Med. 2016;9(6):11202–10.

    Google Scholar 

  84. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.

    Article  CAS  PubMed  Google Scholar 

  85. US Food and Drug Administration. Guidance for industry. Diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov. Accessed 1 Nov 2016.

  86. Zannad F, Stough WG, Lipicky RJ, et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J. 2016;2:200–5.

    Google Scholar 

  87. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–76.

    Article  CAS  PubMed  Google Scholar 

  88. Krum H, Skiba M, Wu S, et al. Heart failure and dipeptidyl peptidase-4 inhibitors. Eur J Heart Fail. 2014;16:603–7.

    Article  CAS  PubMed  Google Scholar 

  89. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assesment. N Eng J Med. 2014;370(9):794–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of sitagliptin was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Lesley J. Scott

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: J.C. De Lima-Júnior, Obesity and Comorbidities Research Center, Department of Internal Medicine, University of Campinas, Campinas, Sao Paulo, Brazil; M. C. Mancini, Sao Paulo University, Endocrinology and Metabology Service, Obesity and Metabolism Syndrome Group, Sao Paulo, Brazil; N. Papanas, Democritus University of Thrace, Diabetes Centre, Second Department of Internal Medicine, Alexandroupolis, Greece; Y. Saisho, Keio University School of Medicine, Department of Internal Medicine, Tokyo, Japan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Sitagliptin: A Review in Type 2 Diabetes. Drugs 77, 209–224 (2017). https://doi.org/10.1007/s40265-016-0686-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0686-9

Keywords

Search

Navigation